Mary Broadfoot Walker

Mary Broadfoot Walker (1888 - 1974)

Mary Broadfoot Walker (1888 – 1974) was a Scottish physician

Whilst working at the Poor Law Service in London, Walker noticed that the symptoms and signs of myasthenia gravis had some similarities with curare poisoning. She injected physostigmine subcutaneously into a patient with severe myasthenia and demonstrated that it caused temporary improvement of symptoms. Her 1934 findings were initially met with skepticism. A year later she demonstrated the demonstrated the dramatic effect of the better tolerated neostigmine to the clinical section of the Royal Society of Medicine (1935).

Walker also published the first report demonstrating the relationship of hypokalemia with familial periodic paralysis (1935).

Dr. Mary B. Walker was a shy, unobtrusive and almost self-effacing physician. However, she was intense, thoughtful, and perceptive in her analysis of patient problems. She was never appointed into the grandeur of any research institution or even a major hospital. She maintained correspondence with many of the people she had treated for myasthenia gravis and published a leading editorial article in the British Medical Journal shortly before she died.

  • Born 17 April 1888 in Croft-an-Righ, Wigtown, Scotland
  • 1913 – MB, University of Edinburgh (Edinburgh College of Medicine for Women)
  • 1916 – 1919 – RAMC served in Malta and Salonika
  • 1920-1936 – Assistant Medical Officer in the “Poor Law Service” based at St. Alfege’s Hospital, Greenwich
  • 1932 – MRCP (London) . She then worked at St Leonard’s Hospital, Shoreditch, St Francis’ Hospital, Dulwich, and St Benedict’s Hospital, Tooting.
  • 1934 – Whilst working at St Alfege’s Hospital, Walker discovered that the subcutaneous injection of physostigmine could temporarily reverse the muscle weakness found in patients suffering from myasthenia gravis. She published a letter on the matter, the ‘Treatment of myasthenia gravis with physostigmine‘ in the Lancet on 2 June 1934
  • 1935 – The first of 3 cases described in the 1934 publication formed the bases of her MD thesis at the University of Edinburgh: Contribution to the study of Myasthenia Gravis – for which she received the Thesis Gold Medal from the Faculty of Medicine of Edinburgh University. Dr. Walker ended her MD thesis with the sentence: “No case of myasthenia gravis should now die of the disease”
  • 1935 – Walker was the first to recognize the association between familial periodic paralysis and hypokalaemia (1935c).
  • 1938 – Invited as honorary staff to the Elizabeth Garrett Anderson Hospital, but declined as financial constraints limited her to a salaried post
  • 1954 – Retired to Croft–an–Righ, Wigtown though she continued to work part-time at the Glasgow Royal Maternity and Women’s Hospital, and remained active in the field of myasthenia gravis.
  • 1962 – Walker was the first woman to receive the Jean Hunter Prize administered by the Royal College of Physicians for ‘the advancement of research into the treatment of nervous exhaustion and for her original contribution to the fundamental knowledge of the nature of myasthenia gravis, made while carrying out the routine duties of a medical officer at a large metropolitan hospital.‘ She was 75 years old. Dr. Walker did not travel to receive Jean Hunter Prize.
  • Died 13 September 1974

Medical Eponyms
Mary Walker effect (1934)

In 1934 Mary Walker discovered that physostigmine and Prostigmin (neostigmine) temporarily restored muscle function in patients with myasthenia gravis.

In a letter to The Lancet, that she recorded improvement in myasthenia gravis following injections of physostigmine, and suggested that “it may be significant that physostigmine inhibits the action of the esterase that destroys acetylcholine”.

In the following year she demonstrated at the Royal Society of Medicine two cases where myasthenia was relieved by prostigmin, which she later showed could also be administered orally. Myasthenia gravis and its treatment were the subject of her M.D. thesis, for which she was awarded a gold medal in 1935.

Today, after the discovery of Prostigmin (neostigmine), it is still used in adult cases of myasthenia gravis who are notable to tolerate pyridostigmine and is the first drug of choice for myasthenia gravis in childhood. Prostigmin also has a role in some disorders of gut motility.

Major Publications




Graduated from Southampton Medical School in 2017 with BMBS. Working in Sir Charles Gairdner Hospital Emergency Department in Perth, Australia.

BA MA (Oxon) MBChB (Edin) FACEM FFSEM. Emergency physician, Sir Charles Gairdner Hospital.  Passion for rugby; medical history; medical education; and asynchronous learning #FOAMed evangelist. Co-founder and CTO of Life in the Fast lane | Eponyms | Books | Twitter |

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.